Guggenheim initiated coverage on 2seventy bio with a new price target
$TSVT
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of 2seventy bio with a rating of Buy and set a new price target of $30.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/6/2024 | $5.00 → $2.00 | Neutral → Sell | Goldman |
| 1/31/2024 | Outperform → Market Perform | TD Cowen | |
| 1/31/2024 | $5.00 → $18.00 | Market Perform → Outperform | Leerink Partners |
| 10/30/2023 | $6.00 | Outperform → Market Perform | Leerink Partners |
| 10/12/2023 | $13.00 | Buy | Citigroup |
| 9/13/2023 | $5.00 | Buy → Neutral | Goldman |
| 9/12/2023 | Buy → Neutral | Guggenheim | |
| 7/28/2023 | $25.00 → $13.00 | Overweight → Equal-Weight | Morgan Stanley |
Goldman downgraded 2seventy bio from Neutral to Sell and set a new price target of $2.00 from $5.00 previously
TD Cowen downgraded 2seventy bio from Outperform to Market Perform
Leerink Partners upgraded 2seventy bio from Market Perform to Outperform and set a new price target of $18.00 from $5.00 previously
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
15-12G - 2seventy bio, Inc. (0001860782) (Filer)
EFFECT - 2seventy bio, Inc. (0001860782) (Filer)
POS AM - 2seventy bio, Inc. (0001860782) (Filer)